New drugs for treatment of severe acute radiation sickness: Research advances / 国际药学研究杂志

ABSTRACT

Through efforts of several generations over the past half century, great advances have been achieved in the development of radiation countermeasures for the acute radiation sickness (ARS). Convergent studies have disclosed numerous radioprotectants with significant radioprotective efficacy which include granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), thrombopoietin (TPO), interleukin-12, derivatives of the bacterial flagellin, androst-5-ene-3β, 17β-diol (AED), beclomethasone 17, 21-dipropionate (BDP), vitamin E (and its)derivatives, and genistein. particularly, the two growth factors G-CSF and TPO show greater radioprotective effects. In this paper, we summarize the radioprotective effects of compounds or biological agents on severe ARS (SARS), which have been evaluated in large animal models or assembled into a nuclear accident emergency treatment medicine box, and review their research advances in recent years.